For research use only. Not for therapeutic Use.
Rotigaptide is a peptide-based drug that enhances gap junction communication by selectively modulating connexin 43 (Cx43) channels. Gap junctions are critical for cell-to-cell communication, particularly in the heart, where they help synchronize cardiac muscle contractions. Rotigaptide is primarily studied for its potential in preventing and treating cardiac arrhythmias, especially those related to ischemia and atrial fibrillation. By improving electrical coupling between heart cells, rotigaptide helps maintain normal heart rhythm, reducing the risk of arrhythmias. Its ability to enhance gap junction function makes it a promising therapeutic candidate in cardiovascular research and arrhythmia management.
Catalog Number | I008729 |
CAS Number | 355151-12-1 |
Synonyms | GAP-486; ZP-123; GAP486; ZP123; GAP 486; ZP 123; Rotigaptide.;Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- |
Molecular Formula | C28H39N7O9 |
Purity | ≥95% |
Target | Gap Junction Protein |
Solubility | Soluble in DMSO |
Storage | 0 - 4 °C for short term, or -20 °C for long term |
IUPAC Name | (2R,4S)-1-[(2R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]-N-[2-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-4-hydroxypyrrolidine-2-carboxamide |
InChI | InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1 |
InChIKey | GFJRASPBQLDRRY-TWTQBQJDSA-N |
SMILES | CC(C(=O)NCC(=O)N)NC(=O)CNC(=O)C1CC(CN1C(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C)O |